WO2023216317A1 - Method for synthesizing nirmatrelvir intermediate - Google Patents

Method for synthesizing nirmatrelvir intermediate Download PDF

Info

Publication number
WO2023216317A1
WO2023216317A1 PCT/CN2022/094641 CN2022094641W WO2023216317A1 WO 2023216317 A1 WO2023216317 A1 WO 2023216317A1 CN 2022094641 W CN2022094641 W CN 2022094641W WO 2023216317 A1 WO2023216317 A1 WO 2023216317A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
reaction
synthesis method
solvent
organic phase
Prior art date
Application number
PCT/CN2022/094641
Other languages
French (fr)
Chinese (zh)
Inventor
刘国杰
胡毅方
田湘寅
王鹏
张文灵
钱刚
Original Assignee
杭州国瑞生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州国瑞生物科技有限公司 filed Critical 杭州国瑞生物科技有限公司
Publication of WO2023216317A1 publication Critical patent/WO2023216317A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to the field of synthesis technology, specifically a method for synthesizing nematvir intermediates.
  • Patent US2008/0027262 reports using Boc-L-hydroxyproline methyl ester as raw material and directly eliminating it with T3P solution (ethyl acetate solution of 1-propyl cyclic phosphoric anhydride) to obtain the product, with a yield of 97% and an ee value of: 99%; however, T3P is expensive and the country controls dangerous goods, so this route has no industrial value.
  • T3P solution ethyl acetate solution of 1-propyl cyclic phosphoric anhydride
  • Patent US2008/318923 reports the use of Boc-L-iodoproline methyl ester as the raw material and elimination with DBU to obtain the product, but there will be about 10-20% of the ectopically eliminated isomer (Formula IV), making it difficult to separate.
  • Patent CN109232612 reports that Boc-L-hydroxyproline methyl ester is used as raw material, Ms is added to the hydroxyl group first, and then the product is obtained by eliminating diphenyl diselenide and sodium borohydride. This method is complex to operate and the price of diphenyl diselenide is high. Difficult to use in industrialization.
  • the present invention provides a synthesis method of nematvir intermediate, which has low cost, stable process, high purity and yield of synthetic products, and is suitable for industrial production.
  • the invention provides a synthesis method of nematvir intermediate, which includes the following steps:
  • R1 is hydrogen, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, one of p-methoxybenzyl;
  • R is hydrogen, methyl, ethyl, n-propyl, isopropyl, tert-butyl one of them.
  • the solvent in step (1) includes one of dichloromethane, 1,2-dichloroethane, chloroform, and tetrahydrofuran.
  • the solvent is methylene chloride.
  • the base in step (2) includes one or more of pyridine, triethylamine, N,N-diisopropylethylamine, potassium carbonate, and sodium carbonate.
  • the base is N,N-diisopropylethylamine.
  • step (1) the molar ratio of formula V and trifluoromethanesulfonic anhydride described in step (1) is: 1:1.1-1.5.
  • weight ratio of formula V and solvent described in step (1) is: 1:5-10.
  • step (2) the molar ratio of formula V and DBU in step (2) is: 1:1.1-1.5.
  • step (1) specifically includes: dissolving Formula V in a solvent, adding a base, cooling, adding trifluoromethanesulfonic anhydride, reacting, adding water to stir, and separating the liquids to obtain the lower organic phase, washing, drying, and filtering, Obtain filtrate.
  • step (1) specifically includes: adding Boc-L-hydroxyproline methyl ester to the reaction bottle and dissolving it in dichloromethane, adding DIPEA for cooling, and adding trifluoromethanesulfonic anhydride and dichloromethane. Mix to make a dilute solution, transfer to the dropping funnel, add the above dilute solution dropwise into the reaction system containing the raw materials, control the temperature to 0-10°C, continue the reaction after the dripping, and control the temperature (you can use TLC to monitor, high Potassium manganate develops color); after the reaction, add water, stir, and separate the liquids.
  • the lower organic phase is washed with 1 mol/L dilute hydrochloric acid (50 mL), and then washed with 50 mL.
  • the organic phase was dried by adding anhydrous sodium sulfate. Filter, and wash the filter cake with dichloromethane; combine the filtrate and use it directly for the next reaction.
  • step (1) specifically includes: adding 49g Boc-L-hydroxyproline methyl ester into the reaction bottle and dissolving it in 300mL methylene chloride, adding 31g of DIPEA and cooling to 0-10°C. Mix 62 grams of fluomethanesulfonic anhydride and 49 mL of methylene chloride to make a dilute solution. Transfer it to a dropping funnel. Add the above dilute solution dropwise to the reaction system containing the raw materials. Control the temperature to 0-10°C and continue after dripping.
  • step (2) specifically includes: adding DBU dropwise to the formula VI to react, continuing the reaction after the dropwise addition is completed, adding water, stirring, and liquid separation, and the obtained lower organic phase is washed, dried, filtered, and rinsed. After washing, the concentrated solution is concentrated to dryness to obtain the product of formula III.
  • step (2) specifically includes: cooling the filtrate obtained in step (1), adding DBU dropwise, the reaction is exothermic, and controlling the reaction temperature to 0-10°C; continuing the reaction after dripping, and controlling the temperature to 0-10°C. 10°C (TLC can be used to monitor, and potassium permanganate can develop color); after the reaction is completed, add water, stir, and separate the liquids.
  • the lower organic phase is washed with 1 mol/L dilute hydrochloric acid (50 mL), and then washed with 50 mL.
  • the organic phase was dried over anhydrous sodium sulfate, filtered, rinsed, and the filtrate was concentrated to dryness to obtain an oily substance.
  • step (1) specifically includes: cooling the filtrate obtained in step (1) to 0-10°C, adding DBU (36.5 g) dropwise, the reaction is exothermic, and controlling the reaction temperature to 0-10°C; After the dripping, continue the reaction for 4-8 hours, and control the temperature to 0-10°C (you can use TLC to monitor and potassium permanganate to develop color); after the reaction is completed, add 150mL of water, stir for 5-10 minutes, separate the liquids, and use the lower organic phase. Wash with 1 mol/L dilute hydrochloric acid (50 mL), and then wash with 50 mL. The organic phase was dried over anhydrous sodium sulfate, filtered, rinsed, and the filtrate was concentrated to dryness to obtain an oily substance.
  • DBU 36.5 g
  • reaction temperatures in steps (1) and (2) are both 0-30°C; preferably 0-10°C.
  • Figure 1 is a GC chart of the nematvir intermediate synthesized in the present invention.
  • a method for synthesizing nematvir intermediates including the following steps:
  • Peak number keep time area high area(%) 1 8.508 3146 705 0.033 2 8.564 4916 715 0.051 3 9.352 2954 516 0.031 4 9.962 1577 181 0.016 5 10.985 1691 256 0.018 6 11.359 1565 178 0.016 7 11.592 5011 865 0.052 8 12.249 9446781 1627018 97.802
  • a method for synthesizing nematvir intermediates including the following steps:
  • a method for synthesizing nematvir intermediates including the following steps:
  • Example 1 The only difference between the synthesis method of nematvir intermediate and Example 1 is that methylsulfonyl chloride is used instead of trifluoromethanesulfonyl chloride; the result is that the GC purity is 96.3%, the yield is 92.3%, and the content is 95.7%, but The ee value is 15%, and the product is racemized.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Provided is a method for synthesizing a nirmatrelvir intermediate in formula (III), specifically comprising: (1) dissolving a compound represented by formula V in a solvent, and reacting with trifluoromethanesulfonic anhydride under an alkaline condition to give a compound represented by formula VI; and (2) adding DBU to the compound represented by formula VI for an elimination reaction to give a product represented by formula III. The method features cost-efficiency, a stable process, and a high purity and high yield of the synthesized product, and is suitable for industrial production.

Description

一种奈玛特韦中间体的合成方法A kind of synthesis method of nematvir intermediate 技术领域Technical field
本发明涉及合成技术领域,具体一种奈玛特韦中间体的合成方法。The present invention relates to the field of synthesis technology, specifically a method for synthesizing nematvir intermediates.
背景技术Background technique
(1R,2S,5S)-6,6-二甲基-3-氮杂双环[3,1,0]己基-2-羧酸酯(式(I)所示化合物)及其相应的盐是美国辉瑞公司公开的其Covid-19治疗药物Paxlovid组成之一奈玛特韦(Nirmatrelvir,PF-07321332,式(II)所示化合物)的重要中间体。目前专利CN114057627A公开一条新路线合成方法,其中重要原料结构为式(III):(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexyl-2-carboxylate (compound represented by formula (I)) and its corresponding salt are Pfizer of the United States disclosed that it is an important intermediate of nirmatrelvir (PF-07321332, a compound represented by formula (II)), one of the components of its Covid-19 treatment drug Paxlovid. At present, patent CN114057627A discloses a new route synthesis method, in which the important raw material structure is formula (III):
Figure PCTCN2022094641-appb-000001
Figure PCTCN2022094641-appb-000001
目前式III的合成方法如下:The current synthesis method of formula III is as follows:
专利US2008/0027262报道了以Boc-L-羟脯氨酸甲酯为原料,用T3P溶液(1-丙基环磷酸酐的乙酸乙酯溶液)直接消除得到产物,收率97%,ee值:99%;但是T3P价格高昂且国家管制危险品,所以该路线没有工业化的价值。Patent US2008/0027262 reports using Boc-L-hydroxyproline methyl ester as raw material and directly eliminating it with T3P solution (ethyl acetate solution of 1-propyl cyclic phosphoric anhydride) to obtain the product, with a yield of 97% and an ee value of: 99%; however, T3P is expensive and the country controls dangerous goods, so this route has no industrial value.
专利US2008/318923报道了使用Boc-L-碘代脯氨酸甲酯为原料,用DBU消除得到产物,但会有10-20%左右的异位消除异构体(式IV),难以分离。Patent US2008/318923 reports the use of Boc-L-iodoproline methyl ester as the raw material and elimination with DBU to obtain the product, but there will be about 10-20% of the ectopically eliminated isomer (Formula IV), making it difficult to separate.
Figure PCTCN2022094641-appb-000002
Figure PCTCN2022094641-appb-000002
专利CN109232612报道了Boc-L-羟脯氨酸甲酯为原料,先羟基上Ms,然后用二苯基二硒和硼氢化钠消除得到产物,该方法操作复杂,二苯基二硒价格高,难以用于工业化。Patent CN109232612 reports that Boc-L-hydroxyproline methyl ester is used as raw material, Ms is added to the hydroxyl group first, and then the product is obtained by eliminating diphenyl diselenide and sodium borohydride. This method is complex to operate and the price of diphenyl diselenide is high. Difficult to use in industrialization.
针对现有技术合成方法存在的操作复杂、成本高、纯度低以及难以工业化等各类问题,寻找一种成本低廉、工艺稳定、合成产物纯度以及收率较高,适用于工业化生产的奈玛特韦中间体的合成方法十分必要。In view of the various problems existing in the existing technical synthesis methods, such as complex operation, high cost, low purity and difficulty in industrialization, we are looking for a low-cost, stable process, high purity and yield of synthetic products, suitable for industrial production of nemat The synthesis method of Wei intermediate is very necessary.
发明内容Contents of the invention
本发明针对现有技术存在的问题,提供了一种奈玛特韦中间体的合成方法,该方法成本低廉、工艺稳定、合成产物纯度以及收率较高,适用于工业化生产。In view of the problems existing in the prior art, the present invention provides a synthesis method of nematvir intermediate, which has low cost, stable process, high purity and yield of synthetic products, and is suitable for industrial production.
为实现上述目的,本发明采用的技术方案如下:In order to achieve the above objects, the technical solutions adopted by the present invention are as follows:
本发明提供了一种奈玛特韦中间体的合成方法,包括以下步骤:The invention provides a synthesis method of nematvir intermediate, which includes the following steps:
(1)将式V溶于溶剂中,在碱性条件下与三氟甲磺酸酐反应,得到式VI;(1) Dissolve formula V in a solvent and react with trifluoromethanesulfonic anhydride under alkaline conditions to obtain formula VI;
(2)向式VI中加入DBU,消除反应得到的式III产物;(2) Add DBU to Formula VI to eliminate the product of Formula III obtained by the reaction;
反应式具体如下所示:The reaction formula is as follows:
Figure PCTCN2022094641-appb-000003
Figure PCTCN2022094641-appb-000003
其中,R1为氢,叔丁氧羰基,苄氧羰基,苄基,对甲氧基苄基中的一种;R为氢,甲基, 乙基,正丙基,异丙基,叔丁基中的一种。Among them, R1 is hydrogen, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, one of p-methoxybenzyl; R is hydrogen, methyl, ethyl, n-propyl, isopropyl, tert-butyl one of them.
进一步地,步骤(1)中所述溶剂包括二氯甲烷,1,2-二氯乙烷,氯仿,四氢呋喃中的一种。Further, the solvent in step (1) includes one of dichloromethane, 1,2-dichloroethane, chloroform, and tetrahydrofuran.
进一步地,所述溶剂为二氯甲烷。Further, the solvent is methylene chloride.
进一步地,步骤(2)中所述碱包括吡啶、三乙胺、N,N-二异丙基乙胺、碳酸钾、碳酸钠中的一种或多种。Further, the base in step (2) includes one or more of pyridine, triethylamine, N,N-diisopropylethylamine, potassium carbonate, and sodium carbonate.
进一步地,所述碱为N,N-二异丙基乙胺。Further, the base is N,N-diisopropylethylamine.
进一步地,步骤(1)中所述式V、三氟甲磺酸酐的摩尔比为:1:1.1-1.5。Further, the molar ratio of formula V and trifluoromethanesulfonic anhydride described in step (1) is: 1:1.1-1.5.
进一步地,步骤(1)中所述式V、溶剂的重量比为:1:5-10。Further, the weight ratio of formula V and solvent described in step (1) is: 1:5-10.
进一步地,步骤(2)中式V和DBU的摩尔比为:1:1.1-1.5。Further, the molar ratio of formula V and DBU in step (2) is: 1:1.1-1.5.
进一步地,步骤(1)具体包括:将式V溶于溶剂中,加入碱后,冷却,加入三氟甲磺酸酐,反应,加水搅拌,分液,得到下层有机相,洗涤、干燥,过滤,得到滤液。Further, step (1) specifically includes: dissolving Formula V in a solvent, adding a base, cooling, adding trifluoromethanesulfonic anhydride, reacting, adding water to stir, and separating the liquids to obtain the lower organic phase, washing, drying, and filtering, Obtain filtrate.
在一些具体的实施方式中,步骤(1)具体包括:反应瓶中加入Boc-L-羟脯氨酸甲酯溶于二氯甲烷中,加入DIPEA冷却,将三氟甲磺酸酐与二氯甲烷混合,制成稀溶液,转移至滴液漏斗中,将上制稀溶液滴加至含原料的反应体系中,控制温度0-10℃,滴完继续反应,控制温度(可以使用TLC监控,高锰酸钾显色);反应完后,加入水,搅拌,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相加入无水硫酸钠干燥。过滤,滤饼用二氯甲烷洗涤;合并滤液直接用于下一步反应。In some specific embodiments, step (1) specifically includes: adding Boc-L-hydroxyproline methyl ester to the reaction bottle and dissolving it in dichloromethane, adding DIPEA for cooling, and adding trifluoromethanesulfonic anhydride and dichloromethane. Mix to make a dilute solution, transfer to the dropping funnel, add the above dilute solution dropwise into the reaction system containing the raw materials, control the temperature to 0-10°C, continue the reaction after the dripping, and control the temperature (you can use TLC to monitor, high Potassium manganate develops color); after the reaction, add water, stir, and separate the liquids. The lower organic phase is washed with 1 mol/L dilute hydrochloric acid (50 mL), and then washed with 50 mL. The organic phase was dried by adding anhydrous sodium sulfate. Filter, and wash the filter cake with dichloromethane; combine the filtrate and use it directly for the next reaction.
在一些优选的实施方式中,步骤(1)具体包括:反应瓶中加入49g Boc-L-羟脯氨酸甲酯溶于300mL二氯甲烷中,加入DIPEA 31克冷却至0-10℃将三氟甲磺酸酐62克与二氯甲烷49mL混合,制成稀溶液,转移至滴液漏斗中,将上制稀溶液滴加至含原料的反应体系中,控制温度0-10℃,滴完继续反应1-2小时,控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入150mL水,搅拌5-10分钟,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相加入49克无水硫酸钠干燥0.5小时。过滤,滤饼用49mL二氯甲烷洗涤;合并滤液直接用于下一步反应。In some preferred embodiments, step (1) specifically includes: adding 49g Boc-L-hydroxyproline methyl ester into the reaction bottle and dissolving it in 300mL methylene chloride, adding 31g of DIPEA and cooling to 0-10°C. Mix 62 grams of fluomethanesulfonic anhydride and 49 mL of methylene chloride to make a dilute solution. Transfer it to a dropping funnel. Add the above dilute solution dropwise to the reaction system containing the raw materials. Control the temperature to 0-10°C and continue after dripping. React for 1-2 hours, control the temperature to 0-10°C (you can use TLC to monitor and potassium permanganate to develop color); after the reaction, add 150mL of water, stir for 5-10 minutes, separate the liquids, and use 1mol/L for the lower organic phase. Wash with dilute hydrochloric acid (50 mL), and then wash with 50 mL. Add 49 grams of anhydrous sodium sulfate to the organic phase and dry for 0.5 hours. Filter, and wash the filter cake with 49 mL of methylene chloride; combine the filtrate and use it directly for the next reaction.
进一步地,步骤(2)具体包括:向式VI中滴加DBU反应,滴加完后继续反应,反应完成后,加入水,搅拌、分液,得到的下层有机相洗涤、干燥、过滤、淋洗后,将浓缩液浓 缩至干后,即得式III产物。Further, step (2) specifically includes: adding DBU dropwise to the formula VI to react, continuing the reaction after the dropwise addition is completed, adding water, stirring, and liquid separation, and the obtained lower organic phase is washed, dried, filtered, and rinsed. After washing, the concentrated solution is concentrated to dryness to obtain the product of formula III.
在一些具体的实施方式中,步骤(2)具体包括:将步骤(1)得到的滤液冷却,滴加DBU,反应放热,控制反应温度0-10℃;滴完继续反应,控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入水,搅拌,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相用无水硫酸钠干燥后,过滤,淋洗,滤液浓缩至干,得到油状物。In some specific embodiments, step (2) specifically includes: cooling the filtrate obtained in step (1), adding DBU dropwise, the reaction is exothermic, and controlling the reaction temperature to 0-10°C; continuing the reaction after dripping, and controlling the temperature to 0-10°C. 10°C (TLC can be used to monitor, and potassium permanganate can develop color); after the reaction is completed, add water, stir, and separate the liquids. The lower organic phase is washed with 1 mol/L dilute hydrochloric acid (50 mL), and then washed with 50 mL. The organic phase was dried over anhydrous sodium sulfate, filtered, rinsed, and the filtrate was concentrated to dryness to obtain an oily substance.
在一些优选的实施方式中,步骤(1)具体包括:将步骤(1)得到的滤液冷却至0-10℃,滴加DBU(36.5克),反应放热,控制反应温度0-10℃;滴完继续反应4-8小时,控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入150mL水,搅拌5-10分钟,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相用无水硫酸钠干燥后,过滤,淋洗,滤液浓缩至干,得到油状物。In some preferred embodiments, step (1) specifically includes: cooling the filtrate obtained in step (1) to 0-10°C, adding DBU (36.5 g) dropwise, the reaction is exothermic, and controlling the reaction temperature to 0-10°C; After the dripping, continue the reaction for 4-8 hours, and control the temperature to 0-10°C (you can use TLC to monitor and potassium permanganate to develop color); after the reaction is completed, add 150mL of water, stir for 5-10 minutes, separate the liquids, and use the lower organic phase. Wash with 1 mol/L dilute hydrochloric acid (50 mL), and then wash with 50 mL. The organic phase was dried over anhydrous sodium sulfate, filtered, rinsed, and the filtrate was concentrated to dryness to obtain an oily substance.
进一步地,步骤(1)和(2)中所述反应的温度均为0-30℃;优选为0-10℃。Further, the reaction temperatures in steps (1) and (2) are both 0-30°C; preferably 0-10°C.
本发明所取得的技术效果是:The technical effects achieved by the present invention are:
优化创新合成奈玛特韦中间体的新路线,使之能直接用于工业化生产,同时成本低廉,工艺稳定安全。产品纯度达到95%以上,ee值>99%,收率可达90%,含量95%以上;且可以不用柱层析分离纯化,能直接用于下一步反应。Optimize and innovate a new route for the synthesis of nematvir intermediates so that they can be directly used in industrial production with low cost and stable and safe processes. The product purity reaches more than 95%, the ee value is >99%, the yield can reach 90%, and the content is more than 95%; it can be separated and purified without column chromatography and can be directly used in the next step of the reaction.
附图说明Description of the drawings
图1为本发明中合成的奈玛特韦中间体的GC图谱。Figure 1 is a GC chart of the nematvir intermediate synthesized in the present invention.
具体实施方式Detailed ways
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。The following describes the embodiments of the present invention through specific examples. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments. Various details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
在进一步描述本发明具体实施方式之前,应理解,本发明的保护范围不局限于下述特定的具体实施方案;还应当理解,本发明实施例中使用的术语是为了描述特定的具体实施方案,而不是为了限制本发明的保护范围。Before further describing the specific embodiments of the present invention, it should be understood that the protection scope of the present invention is not limited to the following specific specific embodiments; it should also be understood that the terms used in the embodiments of the present invention are for describing specific specific embodiments, It is not intended to limit the scope of the present invention.
当实施例给出数值范围时,应理解,除非本发明另有说明,每个数值范围的两个端点以 及两个端点之间任何一个数值均可选用。除非另外定义,本文中使用的所有技术和科学术语具有与本发明所属技术领域的普通技术人员通常理解的相同意义。When the examples give numerical ranges, it should be understood that, unless otherwise stated in the invention, the two endpoints of each numerical range and any value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
值得说明的是,本发明中使用的原料均为普通市售产品,因此对其来源不做具体限定。It is worth noting that the raw materials used in the present invention are all common commercially available products, so their sources are not specifically limited.
实施例1Example 1
一种奈玛特韦中间体的合成方法,包括以下步骤:A method for synthesizing nematvir intermediates, including the following steps:
(1)反应瓶中加入49g Boc-L-羟脯氨酸甲酯溶于300mL二氯甲烷中,加入DIPEA 31克冷却至0-10℃;将三氟甲磺酸酐62克与二氯甲烷49mL混合,制成稀溶液,转移至滴液漏斗中,将上制稀溶液滴加至含原料的反应体系中,控制温度0-10℃,滴完继续反应1-2小时,控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入150mL水,搅拌5-10分钟,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相加入49克无水硫酸钠干燥0.5小时。过滤,滤饼用49mL二氯甲烷洗涤;合并滤液直接用于下一步反应;(1) Add 49g Boc-L-hydroxyproline methyl ester into the reaction bottle and dissolve it in 300mL dichloromethane, add 31g DIPEA and cool to 0-10°C; mix 62g trifluoromethanesulfonic anhydride and 49mL dichloromethane Mix to make a dilute solution, transfer to the dropping funnel, add the above dilute solution dropwise into the reaction system containing the raw materials, control the temperature to 0-10°C, continue the reaction for 1-2 hours after the dripping, control the temperature to 0-10 ℃ (TLC can be used to monitor, potassium permanganate color development); after the reaction is completed, add 150mL water, stir for 5-10 minutes, separate the liquids, and wash the lower organic phase with 1mol/L dilute hydrochloric acid (50mL), and then wash with 50mL . Add 49 grams of anhydrous sodium sulfate to the organic phase and dry for 0.5 hours. Filter, and wash the filter cake with 49 mL of methylene chloride; combine the filtrate and use it directly for the next reaction;
(2)将上一步滤液冷却至0-10℃,滴加DBU(36.5克),反应放热,控制反应温度0-10℃;滴完继续反应4-8小时,控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入150mL水,搅拌5-10分钟,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相用无水硫酸钠干燥后,过滤,淋洗,滤液浓缩至干,得到油状物41g,GC:97.8%;收率90.5%,含量95.3%,ee值99.6%(2) Cool the filtrate in the previous step to 0-10°C, add DBU (36.5g) dropwise, the reaction will be exothermic, and control the reaction temperature to 0-10°C; continue the reaction for 4-8 hours after the dripping, and control the temperature to 0-10°C ( TLC can be used to monitor (potassium permanganate color development); after the reaction is completed, add 150 mL of water, stir for 5-10 minutes, separate the liquids, and wash the lower organic phase with 1 mol/L dilute hydrochloric acid (50 mL), and then wash with 50 mL. The organic phase was dried with anhydrous sodium sulfate, filtered, rinsed, and the filtrate was concentrated to dryness to obtain 41 g of oil, GC: 97.8%; yield 90.5%, content 95.3%, ee value 99.6%
具体反应式如下所示:The specific reaction formula is as follows:
Figure PCTCN2022094641-appb-000004
Figure PCTCN2022094641-appb-000004
合成的奈玛特韦中间体的GC图谱如图1所示,其中对应峰号、保留时间、面积、高度等具体如下表所示:The GC spectrum of the synthesized nematvir intermediate is shown in Figure 1. The corresponding peak number, retention time, area, height, etc. are specifically shown in the table below:
表1Table 1
峰号Peak number 保留时间keep time 面积area 高度high 面积(%)area(%)
11 8.5088.508 31463146 705705 0.0330.033
22 8.5648.564 49164916 715715 0.0510.051
33 9.3529.352 29542954 516516 0.0310.031
44 9.9629.962 15771577 181181 0.0160.016
55 10.98510.985 16911691 256256 0.0180.018
66 11.35911.359 15651565 178178 0.0160.016
77 11.59211.592 50115011 865865 0.0520.052
88 12.24912.249 94467819446781 16270181627018 97.80297.802
99 12.66912.669 8163881638 67376737 0.8450.845
1010 12.76912.769 4164941649 51085108 0.4310.431
1111 13.07213.072 72917291 10231023 0.0750.075
1212 13.37013.370 1919019190 29932993 0.1990.199
1313 13.46913.469 2783627836 60096009 0.2880.288
1414 13.78213.782 26882688 438438 0.0280.028
1515 14.50414.504 18671867 450450 0.0190.019
1616 14.93514.935 43324332 629629 0.0450.045
1717 15.47615.476 49904990 12851285 0.0520.052
总计total -- 96591219659121 16551081655108 100.000100.000
实施例2Example 2
一种奈玛特韦中间体的合成方法,包括以下步骤:A method for synthesizing nematvir intermediates, including the following steps:
(1)反应瓶中加入30g(2S,4R)-N-苄氧羰-4-羟基脯氨酸甲酯溶于180mL二氯甲烷中,加入DIPEA 16.6克冷却至0-10℃;将三氟甲磺酸酐34.8克与二氯甲烷30mL混合,制成稀溶液,转移至滴液漏斗中,将上制稀溶液滴加至含原料的反应体系中,控制温度0-10℃,滴完继续反应1-2小时,控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入150mL水,搅拌5-10分钟,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相加入30克无水硫酸钠干燥0.5小时。过滤,滤饼用30mL二氯甲烷洗涤;合并滤液直接用于下一步反应;(1) Add 30g (2S,4R)-N-benzyloxycarbonyl-4-hydroxyproline methyl ester into the reaction bottle and dissolve it in 180mL methylene chloride, add 16.6g of DIPEA and cool to 0-10°C; Mix 34.8 grams of methanesulfonic anhydride and 30 mL of methylene chloride to make a dilute solution. Transfer it to a dropping funnel. Add the above dilute solution dropwise to the reaction system containing the raw materials. Control the temperature to 0-10°C and continue the reaction after the dripping. 1-2 hours, control the temperature to 0-10°C (you can use TLC to monitor and potassium permanganate to develop color); after the reaction is completed, add 150mL of water, stir for 5-10 minutes, separate the layers, and dilute the lower organic phase with 1mol/L Wash with hydrochloric acid (50 mL) and then with 50 mL. Add 30 grams of anhydrous sodium sulfate to the organic phase and dry for 0.5 hours. Filter, and wash the filter cake with 30 mL of methylene chloride; combine the filtrate and use it directly for the next reaction;
(2)将上一步滤液冷却至0-10℃,滴加DBU(19.6克),反应放热,控制反应温度0-10℃;滴完继续反应4-8小时,控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入150mL水,搅拌5-10分钟,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相用无水硫酸钠干燥后,过滤,淋洗,滤液浓缩至干,得到油状物25.0g,GC:98.2%;收率90%,含量96.7%。ee值99.8%(2) Cool the filtrate in the previous step to 0-10°C, add DBU (19.6 g) dropwise, the reaction will be exothermic, and control the reaction temperature to 0-10°C; continue the reaction for 4-8 hours after the dripping, and control the temperature to 0-10°C ( TLC can be used to monitor (potassium permanganate color development); after the reaction is completed, add 150 mL of water, stir for 5-10 minutes, separate the liquids, and wash the lower organic phase with 1 mol/L dilute hydrochloric acid (50 mL), and then wash with 50 mL. The organic phase was dried over anhydrous sodium sulfate, filtered, rinsed, and the filtrate was concentrated to dryness to obtain 25.0 g of oil, GC: 98.2%; yield 90%, content 96.7%. ee value 99.8%
Figure PCTCN2022094641-appb-000005
Figure PCTCN2022094641-appb-000005
实施例3Example 3
一种奈玛特韦中间体的合成方法,包括以下步骤:A method for synthesizing nematvir intermediates, including the following steps:
(1)反应瓶中加入50g Boc-L-羟脯氨酸乙酯溶于300mL二氯甲烷中,加入DIPEA 30克冷却至0-10℃;将三氟甲磺酸酐59.8克与二氯甲烷50mL混合,制成稀溶液,转移至滴液漏斗中,将上制稀溶液滴加至含原料的反应体系中,控制温度0-10℃,滴完继续反应1-2小时, 控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入150mL水,搅拌5-10分钟,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相加入50克无水硫酸钠干燥0.5小时。过滤,滤饼用50mL二氯甲烷洗涤;合并滤液直接用于下一步反应;(1) Add 50g Boc-L-hydroxyproline ethyl ester into the reaction bottle and dissolve it in 300mL dichloromethane, add 30g DIPEA and cool to 0-10°C; mix 59.8g trifluoromethanesulfonic anhydride and 50mL dichloromethane Mix to make a dilute solution, transfer to the dropping funnel, add the above dilute solution dropwise into the reaction system containing the raw materials, control the temperature to 0-10°C, continue the reaction for 1-2 hours after the dripping, control the temperature to 0-10 ℃ (TLC can be used to monitor, potassium permanganate color development); after the reaction is completed, add 150mL water, stir for 5-10 minutes, separate the liquids, and wash the lower organic phase with 1mol/L dilute hydrochloric acid (50mL), and then wash with 50mL . Add 50 grams of anhydrous sodium sulfate to the organic phase and dry for 0.5 hours. Filter, and wash the filter cake with 50 mL of methylene chloride; combine the filtrate and use it directly for the next reaction;
(2)将上一步滤液冷却至0-10℃,滴加DBU(35.2克),反应放热,控制反应温度0-10℃;滴完继续反应4-8小时,控制温度0-10℃(可以使用TLC监控,高锰酸钾显色);反应完后,加入150mL水,搅拌5-10分钟,分液,下层有机相用1mol/L稀盐酸(50mL)洗涤,再用50mL洗涤。有机相用无水硫酸钠干燥后,过滤,淋洗,滤液浓缩至干,得到油状物42.3g,GC:97.3%;收率91.0%,含量95.1%,ee值99.3%(2) Cool the filtrate in the previous step to 0-10°C, add DBU (35.2 g) dropwise, the reaction will be exothermic, and control the reaction temperature to 0-10°C; continue the reaction for 4-8 hours after the dripping, and control the temperature to 0-10°C ( TLC can be used to monitor (potassium permanganate color development); after the reaction is completed, add 150 mL of water, stir for 5-10 minutes, separate the liquids, and wash the lower organic phase with 1 mol/L dilute hydrochloric acid (50 mL), and then wash with 50 mL. The organic phase was dried with anhydrous sodium sulfate, filtered, rinsed, and the filtrate was concentrated to dryness to obtain 42.3g of oil, GC: 97.3%; yield 91.0%, content 95.1%, ee value 99.3%
对比例1Comparative example 1
一种奈玛特韦中间体的合成方法,与实施例1的区别仅在于,用甲基磺酰氯代替三氟甲磺酰氯;结果GC纯度为96.3%,收率92.3%,含量95.7%,但是ee值为15%,产物发生了消旋。The only difference between the synthesis method of nematvir intermediate and Example 1 is that methylsulfonyl chloride is used instead of trifluoromethanesulfonyl chloride; the result is that the GC purity is 96.3%, the yield is 92.3%, and the content is 95.7%, but The ee value is 15%, and the product is racemized.
对比例2Comparative example 2
一种奈玛特韦中间体的合成方法,与实施例1的区别仅在于,三氟甲磺酸酐当量为1.0eq;DBU当量为1.0eq;结果GC纯度为83.2%,原料Boc-L-羟脯氨酸甲酯(V)残留5.6%;中间体VI残留4.3%;收率为85.3%,含量84.2%,ee值为99.6%。The only difference between a synthesis method of nematvir intermediate and Example 1 is that the equivalent of triflate is 1.0eq; the equivalent of DBU is 1.0eq; the resulting GC purity is 83.2%, and the raw material Boc-L-hydroxy Proline methyl ester (V) remains at 5.6%; intermediate VI remains at 4.3%; the yield is 85.3%, the content is 84.2%, and the ee value is 99.6%.
最后应当说明的是,以上内容仅用以说明本发明的技术方案,而非对本发明保护范围的限制,本领域的普通技术人员对本发明的技术方案进行的简单修改或者等同替换,均不脱离本发明技术方案的实质和范围。Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, but does not limit the protection scope of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by those of ordinary skill in the art do not deviate from the scope of the present invention. The essence and scope of the technical solution of the invention.

Claims (10)

  1. 一种奈玛特韦中间体的合成方法,其特征在于:包括以下步骤:A method for synthesizing nematvir intermediates, which is characterized by comprising the following steps:
    (1)将式V溶于溶剂中,在碱性条件下与三氟甲磺酸酐反应,得到式VI;(1) Dissolve formula V in a solvent and react with trifluoromethanesulfonic anhydride under alkaline conditions to obtain formula VI;
    (2)向式VI中加入DBU,消除反应得到的式III产物;(2) Add DBU to Formula VI to eliminate the product of Formula III obtained by the reaction;
    反应式具体如下所示:The reaction formula is as follows:
    Figure PCTCN2022094641-appb-100001
    Figure PCTCN2022094641-appb-100001
    其中,R1为氢,叔丁氧羰基,苄氧羰基,苄基,对甲氧基苄基中的一种;R为氢,甲基,乙基,正丙基,异丙基,叔丁基中的一种。Among them, R1 is one of hydrogen, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl and p-methoxybenzyl; R is hydrogen, methyl, ethyl, n-propyl, isopropyl, tert-butyl one of them.
  2. 根据权利要求1所述的合成方法,其特征在于:步骤(1)中所述溶剂包括二氯甲烷,1,2-二氯乙烷,氯仿,四氢呋喃中的一种。The synthesis method according to claim 1, wherein the solvent in step (1) includes one of methylene chloride, 1,2-dichloroethane, chloroform, and tetrahydrofuran.
  3. 根据权利要求2所述的合成方法,其特征在于:所述溶剂为二氯甲烷。The synthesis method according to claim 2, characterized in that: the solvent is methylene chloride.
  4. 根据权利要求1所述的合成方法,其特征在于:步骤(2)中所述碱包括吡啶、三乙胺、N,N-二异丙基乙胺、碳酸钾、碳酸钠中的一种或多种。The synthesis method according to claim 1, characterized in that: the base in step (2) includes one of pyridine, triethylamine, N,N-diisopropylethylamine, potassium carbonate, sodium carbonate, or Various.
  5. 根据权利要求4所述的合成方法,其特征在于:所述碱为N,N-二异丙基乙胺。The synthesis method according to claim 4, characterized in that: the base is N, N-diisopropylethylamine.
  6. 根据权利要求1所述的合成方法,其特征在于:步骤(1)中所述式V、溶剂、三氟甲磺酸酐的重量比为:1:1.1-1.5。The synthesis method according to claim 1, characterized in that: the weight ratio of formula V, solvent and trifluoromethanesulfonic anhydride in step (1) is: 1:1.1-1.5.
  7. 根据权利要求1所述的合成方法,其特征在于:步骤(2)中式VI和DBU的重量比为1:1.1-1.5。The synthesis method according to claim 1, characterized in that: the weight ratio of formula VI and DBU in step (2) is 1:1.1-1.5.
  8. 根据权利要求1所述的合成方法,其特征在于:步骤(1)具体包括:将式V溶于溶剂中,加入碱后,冷却,加入三氟甲磺酸酐,反应,加水搅拌,分液,得到下层有机相,洗涤、干燥,过滤,得到滤液。The synthesis method according to claim 1, characterized in that: step (1) specifically includes: dissolving formula V in a solvent, adding a base, cooling, adding trifluoromethanesulfonic anhydride, reacting, adding water, stirring, and liquid separation, Obtain the lower organic phase, wash, dry, and filter to obtain the filtrate.
  9. 根据权利要求1所述的合成方法,其特征在于:步骤(2)具体包括:向式V中滴加DBU反应,滴加完后继续反应,反应完成后,加入水,搅拌、分液,得到的下层有机相洗涤、干燥、过滤、淋洗后,将浓缩液浓缩至干后,即得式III产物。The synthesis method according to claim 1, characterized in that step (2) specifically includes: adding DBU dropwise to the formula V for reaction, continuing the reaction after the dropwise addition, and after the reaction is completed, adding water, stirring, and liquid separation to obtain After the lower organic phase is washed, dried, filtered, and rinsed, the concentrated liquid is concentrated to dryness to obtain the product of Formula III.
  10. 根据权利要求8或9所述的合成方法,其特征在于:步骤(1)和(2)中所述反应的温 度均为0-30℃;优选为0-10℃。The synthetic method according to claim 8 or 9, characterized in that: the temperatures of the reactions described in steps (1) and (2) are both 0-30°C; preferably 0-10°C.
PCT/CN2022/094641 2022-05-09 2022-05-24 Method for synthesizing nirmatrelvir intermediate WO2023216317A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210500180.4 2022-05-09
CN202210500180.4A CN115010638B (en) 2022-05-09 2022-05-09 Synthesis method of Nemactetvir intermediate

Publications (1)

Publication Number Publication Date
WO2023216317A1 true WO2023216317A1 (en) 2023-11-16

Family

ID=83068382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/094641 WO2023216317A1 (en) 2022-05-09 2022-05-24 Method for synthesizing nirmatrelvir intermediate

Country Status (2)

Country Link
CN (1) CN115010638B (en)
WO (1) WO2023216317A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024103319A1 (en) * 2022-11-16 2024-05-23 广东莱佛士制药技术有限公司 Method for synthesizing methyl (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3,1,0]hexyl-2-carboxylate hydrochloride

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379576A (en) * 2012-05-24 2015-02-25 小野药品工业株式会社 Substituted pyrrolidines as factor XIA inhibitors for the treatment thromboembolic diseases
US20210171520A1 (en) * 2017-06-21 2021-06-10 Daiichi Sankyo Company, Limited Ep300/crebbp inhibitor
EP3854783A1 (en) * 2018-09-20 2021-07-28 ONO Pharmaceutical Co., Ltd. Novel salt of 4-(\{(4s)-1-(4-carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-l-prolyl\}amino)benzoic acid, and and novel crystal form of said salt
CN114057627A (en) * 2022-01-18 2022-02-18 南京桦冠生物技术有限公司 Preparation method of hepatitis C and neocorolla drug intermediate and salt thereof
CN114085180A (en) * 2022-01-18 2022-02-25 凯莱英医药集团(天津)股份有限公司 Preparation method of azacyclo derivative intermediate and preparation method of chiral proline derivative intermediate
CN114133350A (en) * 2021-12-16 2022-03-04 浙江乐普药业股份有限公司 Preparation method of anti-neocorolla drug Paxlovid intermediate
CN114436929A (en) * 2021-12-31 2022-05-06 都创(重庆)医药科技有限公司 Synthesis method of N-protected 3, 4-dehydro-L-proline ester

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111233750B (en) * 2020-03-04 2023-12-05 艾琪康医药科技(上海)有限公司 3, 3-difluoro-1, 2,3, 6-tetrahydropiperidine derivative and preparation method thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379576A (en) * 2012-05-24 2015-02-25 小野药品工业株式会社 Substituted pyrrolidines as factor XIA inhibitors for the treatment thromboembolic diseases
US20210171520A1 (en) * 2017-06-21 2021-06-10 Daiichi Sankyo Company, Limited Ep300/crebbp inhibitor
EP3854783A1 (en) * 2018-09-20 2021-07-28 ONO Pharmaceutical Co., Ltd. Novel salt of 4-(\{(4s)-1-(4-carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-l-prolyl\}amino)benzoic acid, and and novel crystal form of said salt
CN114133350A (en) * 2021-12-16 2022-03-04 浙江乐普药业股份有限公司 Preparation method of anti-neocorolla drug Paxlovid intermediate
CN114436929A (en) * 2021-12-31 2022-05-06 都创(重庆)医药科技有限公司 Synthesis method of N-protected 3, 4-dehydro-L-proline ester
CN114057627A (en) * 2022-01-18 2022-02-18 南京桦冠生物技术有限公司 Preparation method of hepatitis C and neocorolla drug intermediate and salt thereof
CN114085180A (en) * 2022-01-18 2022-02-25 凯莱英医药集团(天津)股份有限公司 Preparation method of azacyclo derivative intermediate and preparation method of chiral proline derivative intermediate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KYU-YOUNG KIM, BONG CHAN KIM, HEE BONG LEE, HYUNIK SHIN: "Nucleophilic Fluorination of Triflates by Tetrabutylammonium Bifluoride", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 73, no. 20, 17 October 2008 (2008-10-17), pages 8106 - 8108, XP055012140, ISSN: 00223263, DOI: 10.1021/jo8015659 *
LIU TING; YAN NAN; ZHAO HUI; WANG ZHEN-XING; HU XIANG-GUO: "Synthesis and antibacterial activity of 6(R)- and 6(S)-fluoropenibruguieramine As: Fluorine as a probe for testing the powerfulness of memory of chirality (MOC)", JOURNAL OF FLUORINE CHEMISTRY, ELSEVIER, NL, vol. 207, 3 January 2018 (2018-01-03), NL , pages 18 - 23, XP085342988, ISSN: 0022-1139, DOI: 10.1016/j.jfluchem.2018.01.002 *

Also Published As

Publication number Publication date
CN115010638A (en) 2022-09-06
CN115010638B (en) 2024-02-13

Similar Documents

Publication Publication Date Title
CN114133350B (en) Preparation method of anti-neocrown drug Paxlovid intermediate
CN105102425B (en) The method for preparing bile acid derivative
CN104086379A (en) Method for synthesizing forxiga intermediate
CN110590635A (en) Preparation method of levetiracetam and intermediate thereof
WO2023216317A1 (en) Method for synthesizing nirmatrelvir intermediate
CN111170892A (en) Synthesis method of N-methyl (2S) -2-N-fluorenylmethoxycarbonylamino-aspartic acid (4-tert-butyl ester)
CN112062712A (en) Preparation method of 2- (5-bromo-3-methylpyridin-2-yl) acetic acid hydrochloride
CN111574444A (en) Preparation method of bedaquiline
CN103254265B (en) Abiraterone acetate trifluoroacetate and its preparation method and application
CN111303020A (en) Synthetic method of 5-chloro-2- (pyridine-3-yl) pyridine-3-amine
EP3235797A1 (en) Compound and method for producing same, as well as method for producing oseltamivir phosphate
CN114751849B (en) Preparation method of brivaracetam and intermediate compound
CN105753733A (en) AHU377 crystal form and preparation method and uses thereof
CN106905358B (en) Preparation of vitamin D3Process for preparing analogue intermediates
CN114989061A (en) Preparation method of brivaracetam
CN104530112A (en) Method for preparing everolimus intermediate and ethylated impurities thereof
CN114163411A (en) Preparation method of enantiomer pure dihydromyricetin
CN107629039B (en) The preparation method and intermediate of deuterated acrylamide
CN106045995A (en) Synthesizing method of 5-bromine-1H-pyrrolo[2,3-b]pyridine
CN110483360B (en) Synthesis method of alfaprost alcohol
CN115260074B (en) Preparation method of oral antiviral drug Paxlovid intermediate
CN112778180B (en) Vitamin D 2 Is prepared by the preparation method of (2)
CN113816912B (en) Preparation method of phenazine
CN103435450B (en) A kind of synthetic method of the TMHQ of environmental protection
CN108558862B (en) Synthetic method and intermediate of anti-leukemia cancer cell active molecule

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22941265

Country of ref document: EP

Kind code of ref document: A1